Early Rash Development May Signal Superior Benefit With Lapatinib

Early development of rash identified patients with HER2-positive early breast cancer who received superior benefit from lapatinib-based therapy.

PDF) Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

Lapatinib SpringerLink

PDF) Overnight fasting before lapatinib administration to breast

Lapatinib: Package Insert

Dermatologic Adverse Events

Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?

PDF) Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial

Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+ Trastuzumab Therapy - Cancer Therapy Advisor

Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.

Tykerb: Package Insert / Prescribing Information

Management algorithm for lapatinib- associated rash for nurses/office

Frontiers Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis

Figure 1 from Lapatinib for advanced or metastatic breast cancer.

Dermatologic conditions in women receiving systemic cancer therapy - ScienceDirect

Lapatinib